Tuberculosis (TB) is a deadly infection that occurs in every part of the world. The standard treatment for TB, a six-month multidrug regimen, has not changed in more than 40 years. Patients can ...

For adolescents aged 14 years and older and adults with rifampin-resistant pulmonary TB, a 6-month bedaquiline, pretomanid, and linezolid regimen is as efficacious and safe as the current 15-month ...

A new all-oral six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care, according to results ...

(Medical Xpress)—Aggressive drug regimens used to treat multidrug-resistant tuberculosis reduce the risk of death by about 40 percent when they include at least five drugs likely to be effective ...

Treatment for children with nonsevere tuberculosis can be safely shortened from 6 to 4 months, according to the results of a study published this week in The New England Journal of Medicine.

Almost all patients who received a new treatment for highly drug-resistant tuberculosis are still clear of the disease two years after a medical trial in South Africa, findings from a long-term ...

Findings from the 6-month ZeNix trial indicated that a three-drug regimen for highly resistant tuberculosis was safer and just as effective when it included reduced doses or shorter durations of ...

The treatment for tuberculosis or TB will be shortened from six to four months, the Department of Health announced yesterday.

Hyderabad: Patients of drug-resistant tuberculosis (TB) in the state will soon get a new regimen, which is expected to bring down the cost and also the time of treatment from 20 months to six.BPaLM ...

Berhampur: The state govt has rolled out BPaLM, a shorter duration new treatment regimen for multi-drug resistant tuberculosis (MDR-TB) patients.

Two antibiotics, taken for a month, can stop a leading killer. But “when it’s for TB, people just sort of shrug.” By Apoorva Mandavilli Tuberculosis struck 10 million people worldwide in ...